In individuals with a low diastolic blood pressure (DBP), the potential benefits or risks of intensive systolic blood pressure (SBP) lowering are unclear.
ORIGINAL RESEARCH ARTICLE E levated blood pressure (BP) is an important risk factor for cardiovascular disease (CVD), 1, 2 end-stage kidney disease, 3, 4 and all-cause mortality. 2, 5 Beginning in the 1960s, randomized controlled trials demonstrated the value of treating high diastolic BP (DBP) and subsequently high systolic BP (SBP). 6, 7 Recently, SPRINT (Systolic Blood Pressure Intervention Trial) demonstrated that intensive SBP lowering (SBP target <120 versus <140 mm Hg) improved CVD outcomes and all-cause mortality in adults at high risk for CVD events, 8 even in those ≥75 years of age. 9 Despite the documented value of traditional treatment in adults with a high DBP, 6 intensive therapy to low levels of DBP is controversial. Nearly 30 years ago, a J-shaped relationship was observed between ontreatment DBP and death resulting from myocardial infarction, with the risk being lowest in those with an achieved DBP between 85 and 90 mm Hg and higher at achieved DBP levels on either side of this range. 10, 11 We examined the hypothesis that low baseline DBP adversely modifies the effect of intensive SBP lowering on CVD, kidney disease, and all-cause mortality in SPRINT. 8 In addition, we examined whether baseline pulse pressure (PP) or mean arterial pressure (MAP) modified the effects of the SPRINT intervention.
METHODS
Limited SPRINT data are available through the National Heart, Lung, and Blood Institute at https://biolincc.nhlbi.nih.gov/ studies/sprint_pop for reproducing/replicating the results of this analysis. The Methods section and online-only Data Supplement provide details of the analytical procedures.
SPRINT was a randomized controlled open-label trial that compared the effects of intensive (SBP target <120 mm Hg) and standard (SBP target <140 mm Hg) BP control in 9361 participants from the United States, including Puerto Rico. 8 Details of the SPRINT protocol have been published. 12, 13 Institutional review boards at each of the participating study sites approved the protocol, and all participants provided informed consent.
Study Population
Participants had to be ≥50 years of age with an SBP of 130 to 180 mm Hg and an increased risk of CVD (defined as having at least 1 of the following: clinical or subclinical CVD other than stroke, 10-year risk of CVD ≥15% based on the Framingham global risk indicator, 14 ), proteinuria >1 g/d, polycystic kidney disease, congestive heart failure, dementia, or residence in a nursing home.
Intervention, Follow-Up, and Measurements
Participants were randomly assigned to intensive or standard SBP control, stratified by clinical site. Details of the SPRINT intervention algorithm and medication formulary are provided elsewhere. 12, 13 Participants were seen monthly for 3 months and quarterly thereafter for standardized study visits by trained study staff following protocol requirements. An automated measurement system (model 907XL, Omron Healthcare) was used to record BP at the clinic visit after the participant had been seated for 5 minutes of quiet rest. The mean of 3 BP readings, each 1 minute apart, was used to estimate BP.
Medications were adjusted to target an SBP <120 mm Hg in the intensive treatment group and an SBP of 135 to 139 mm Hg in the standard treatment group. Blood specimens were obtained at each visit for the first 3 months and quarterly thereafter for measurement of serum creatinine. The 4-variable Modification of Diet in Renal Disease equation was used to estimate glomerular filtration rate. 15 Event ascertainment and safety assessments were performed per protocol. 12, 13 
SPRINT Outcomes
The primary outcome was a composite of nonfatal myocardial infarction, acute coronary syndrome not resulting in myocardial infarction, stroke, acute decompensated heart failure, or
Clinical Perspective
What Is New?
• There were U-shaped relationships of baseline diastolic blood pressure (DBP) with the primary cardiovascular disease outcome and all-cause death in SPRINT (Systolic Blood Pressure Intervention Trial).
• However, the beneficial effects of intensive systolic blood pressure lowering (intensive systolic blood pressure goal <120 mm Hg versus standard systolic blood pressure goal <140 mm Hg) on the primary cardiovascular disease outcome and all-cause death were not modified by baseline level of DBP.
• Increased risk of kidney events and serious adverse effects of the intervention was consistent across baseline DBP quintiles. • Therefore, there was no evidence that the benefit of the intensive systolic blood pressure lowering differed by baseline DBP level.
What Are the Clinical Implications?
• Some cohort observational studies and nonrandomized secondary analyses of achieved blood pressures suggested a J-curve relationship of DBP with cardiovascular events.
• Results of current analyses of SPRINT data suggest that underlying processes (such as increased arterial stiffness) that lead to a decline in DBP rather than the level of DBP per se might be the reason for the observed associations of worse outcomes with lower DBP.
• Low levels of DBP within the ranges examined here in SPRINT should not be an impediment to intensive treatment of hypertension, at least in those without diabetes mellitus or stroke.
death resulting from CVD. Death resulting from any cause was a predefined secondary outcome in SPRINT. All outcome events were adjudicated by a committee blinded to treatment assignment. In the present analysis, we also explored a composite CVD outcome that excluded stroke. , confirmed at the next available SPRINT blood draw) in participants without CKD at baseline. In addition, we monitored for serious adverse events as reported earlier. 8 A decision to discontinue the SPRINT BP intervention was made on August 20, 2015, after interim analyses showed that the primary outcome had exceeded preset monitoring boundaries on 2 consecutive occasions. 8 Our analysis is based on information provided in the SPRINT public access BioLINCC database. 16 It includes events that occurred on or before the trial was stopped on August 20, 2015 , and were recognized with the use of a data freeze date of October 14, 2015.
Statistical Methods
We performed all analyses in STATA version MP 14.0 or SAS version 9.4, and we used a 2-sided α=0.05 for hypothesis testing without adjustment for multiple comparisons. We compared baseline characteristics between DBP quintiles using 1-way ANOVA for numeric variables (after log transformation for the albumin-to-creatinine ratio) and used χ 2 tests for categorical variables.
We computed the mean follow-up DBP for each patient by averaging their BP measurements from month 3 to the last reading. We used boxplots to display the patients' mean follow-up DBP values by quintile of baseline DBP within the intensive and standard groups, and we applied 2-sample tests to compare mean follow-up DBP between the lowest and highest quintile of baseline DBP.
We analyzed the association of baseline DBP with the primary and secondary outcomes by fitting a Cox regression model with the randomized SBP intervention and cubic spline terms in baseline DBP as predictor variables, with covariable adjustment for age, sex, and race. We then performed 3 types of analyses based on Cox proportional hazards regression to investigate whether the effects of intensive SBP intervention on the primary and secondary outcomes differed depending on baseline level of DBP. The primary analysis of the interaction between the intensive SBP intervention and baseline DBP, which was specified before initiation of these post hoc analyses, compared the hazard ratio for the effect of intensive SBP intervention on the primary CVD composite outcome between the lowest baseline DBP quintile and the upper 4 quintiles. Second, we investigated the possibility of a more general interaction by fitting a Cox regression for the primary outcome with main effects for the SBP intervention and cubic spline terms for baseline DBP, plus multiplicative interactions between the SBP intervention and the cubic spline terms. In the absence of evidence of a nonlinear interaction (indicated by an interaction P>0.10), we refit the Cox regression using a linear interaction between the SBP intervention and baseline DPB. Third, we provided hazard ratios with 95% confidence intervals to compare the intensive and usual SBP goals within each baseline DPB Results are presented as percents for binary variables, as mean±SD for continuous variables other than ACR, and as median (interquartile range) for ACR. For comparison of differences between the quintiles, P<0.001 for all except never smoked (P=0.57).
ACR indicates albumin-to-creatinine ratio; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; MAP, mean arterial pressure; and PP, pulse pressure.
*Systolic blood pressure at screening visit was used to determine trial eligibility. Baseline visit values are presented in this table.
ORIGINAL RESEARCH ARTICLE quintile. These hazard ratios are presented to provide a comprehensive presentation of the results; however, it is important to note that much or all of the reported variation in hazard ratios between the quintile subgroups is caused by chance and that, in the absence of a statistically significant interaction, the best estimate of the effect of the intervention is given by the study-wide effect estimate, including all patients. We performed similar analyses of the interaction between the SBP intervention and baseline DBP for the secondary outcomes, except that we categorized baseline DBP by a median split rather than quintiles for the kidney composite outcome because of the small number of events for this outcome.
We repeated each of these 3 analyses to evaluate interactions of the BP intervention with baseline MAP and baseline PP. We also provided hazard ratios from Cox regressions comparing the intensive and usual SBP interventions by baseline DBP quintile for the safety outcomes: all serious adverse events, hypotension, syncope, electrolyte abnormality, and acute kidney injury or acute kidney failure.
In participants with and without baseline clinical/subclinical CVD, we performed additional sensitivity analyses in separate Cox models to evaluate the linear interaction of the SPRINT intervention with baseline DBP.
Additional details of the Cox regression models are provided in the online-only Data Supplement.
RESULTS
The mean age of the study population (n=9361) was 67.9±9.4 years, with 35.6% women and 31.5% black.
Mean±SD baseline SBP and DBP were 139.7±15.6 and 78.1±11.9 mm Hg, respectively. Baseline demographic, clinical, and laboratory characteristics of the study population by DBP quintile are summarized in Table 1 . In general, participants with lower DBP tended to be older, have a higher baseline prevalence of CVD and CKD, be on more antihypertensive medications, have a lower baseline SBP and MAP and a higher PP, and have a lower eGFR.
Boxplots displaying the medians and 25th and 75th percentiles of mean follow-up SBP, DBP, PP, and MAP levels by baseline DBP quintile for participants in the intensive and standard arms are presented in Figure 1 . Because the intervention targeted SBP, regardless of baseline DBP, the distribution of achieved mean followup SBP in the intensive arm was similar across baseline quintiles of DBP ( Figure 1A ). Similar findings for achieved SBP across baseline quintiles of DBP were noted in the standard arm ( Figure 1A) . However, the achieved mean follow-up DBP was significantly lower among participants in the lowest compared with the highest quintile of baseline DBP within both the intensive (59.5±6. the highest in the lowest baseline DBP quintile in both the intensive and standard groups ( Figure 1D ).
In the entire cohort, there were 562 primary outcome events over 29 278 person-years of follow-up and 365 all-cause deaths over 30 158 person-years of follow-up. In the subgroup with CKD at baseline, there were 29 kidney composite outcomes over 8490 person-years of follow-up. In the subgroup of participants without CKD at baseline, there were 164 incident CKD events over 21 155 person-years of follow-up.
Adjusted for age, sex, race, and the intervention arm, there was a U-shaped association of baseline DBP with the primary outcome, all-cause deaths, and incident CKD in cubic spline regression analyses ( Figure I in the online-only Data Supplement).
Interactions of Baseline DBP and SBP Intervention for Prespecified Outcomes
In our primary assessment of the interaction between the intensive SBP intervention treatment effect and baseline DBP (Table 2) , the hazard ratio for the primary outcome was 0.78 (95% confidence interval, 0.57-1.07) within the lowest DBP quintile and 0.74 (95% confidence interval, 0.61-0.90) within the upper 4 DBP quintiles (interaction P=0.78). Similarly, there was no evidence of an interaction between intensive SBP intervention and baseline DBP for all-cause death, composite kidney outcome, or incident CKD events ( Table 2) .
The incidence of primary outcome events, all-cause death, and incident CKD (in participants without CKD at baseline) by quintile of baseline DBP is presented in Figure 2 . Within each baseline DBP quintile, participants randomized to the intensive arm had a lower incidence of the primary outcome and all-cause death and a higher incidence of CKD. There was no suggestion of heterogeneity of the hazard ratios for intensive versus standard SBP treatment effect across DBP quintiles for the 3 outcomes studied (Figure 3) . The P values for interaction between treatment effect and baseline quintile of DBP were 0.92, 0.57, and 0.91 for the primary cardiovascular outcome, all-cause mortality, and incident CKD, respectively, in the subgroup without CKD at baseline.
After adjustment for baseline DBP, intensive versus standard SBP treatment had a lower hazard ratio for the primary CVD outcome and all-cause death but a higher hazard for incident CKD (Table 3) . After adjustment for the intervention, participants with a baseline DBP of 61 mm Hg (mean DBP in the lowest baseline DBP quintile) had a higher hazard of the primary outcome, all-cause death, and incident CKD compared with those with a baseline DBP of 78 mm Hg (mean baseline DBP of the entire cohort; Table 3 ). There was no evidence of a nonlinear treatment by baseline DBP interaction for any of the outcomes, and the P values for the linear treatment by baseline DBP interaction did not approach statistical significance for the primary outcome (P=0.85), all-cause death (P=0.37), composite kidney outcome (P=0.57), or incident CKD events (P=0.94; Table 3 ). Similarly, within the subgroups with or without CVD at baseline, there was no evidence of interaction between the intervention and baseline DBP (Tables I and II in the online-only Data Supplement).
Interactions of Baseline DBP and SBP Intervention for the Primary CVD End Point Excluding Stroke
There were 467 nonstroke CVD outcome events over 29 434 person-years of follow-up. There was a U-shaped relation between DBP and the nonstroke CVD outcome ( Figure IIA in the online-only Data Supplement). As for the primary CVD outcome, there was no suggestion of heterogeneity of the hazard ratios for intensive versus standard SBP treatment effect across DBP quintiles when considering the nonstroke CVD outcome ( Figure  IIB in the online-only Data Supplement). There was no evidence of an interaction between baseline DBP-and the SBP-lowering intervention. *HRs comparing the intensive and standard SBP interventions are presented for patients in the lowest baseline DBP quintile subgroup (left) and for patients in the upper 4 baseline DBP quintiles (right). Interaction P values evaluate whether the HRs differed between the 2 baseline DBP subgroups and were computed with likelihood ratio tests for the interaction between the randomized SBP intervention and baseline DBP subgroup in Cox regressions with separate baseline hazards for the 2 baseline DBP subgroups.
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Interactions of Baseline DBP and SBP Intervention for Safety Outcomes
The incidence of safety outcomes (any serious adverse event and serious adverse events associated with hypotension, syncope, electrolyte abnormality, acute kidney injury, or acute kidney failure) is summarized in Table 4 . Those in the lowest quintile of baseline DBP had the highest incidence of these serious adverse events, but there was no evidence for heterogeneity of the effects of the intervention by baseline quintile of DBP.
Interactions of Baseline MAP or PP and SBP Intervention for Prespecified Outcomes and Safety Outcomes
With 1 exception (acute kidney injury by baseline PP), the results were similar for baseline quintiles of Shown are incidence rates and pointwise 95% CIs for the primary cardiovascular disease (CVD) outcome (A), all-cause death (B), and incident chronic kidney disease (CKD; C) in the standard and intensive systolic blood pressure (SBP) groups by quintile of baseline diastolic blood pressure (DBP). The 95% CIs were calculated for incidence rates using the quadratic approximation to the Poisson log likelihood for the log-rate parameter. Lines are drawn between the incidence rates quintiles for the different quintiles for visual clarity, and do not represent fitted regression curves. The analysis of incident CKD patients was performed for patients with baseline estimated glomerular filtration rate ≥60 mL·min .There were too few events to provide a meaningful similar analysis for the composite kidney outcome. 
DISCUSSION
The results of the present study indicate that low baseline DBP was associated with increased risk of primary CVD outcome, but an intervention that actively lowered SBP consistently reduced the risk of the primary CVD outcome across baseline quintiles of DBP.
At some level of low BP, perfusion of organs must become inadequate. On the basis of the on-treatment reports, [17] [18] [19] [20] [21] [22] [23] one might expect individuals with a lower DBP to be at greater risk for adverse outcomes during intensive BP lowering. Because most ventricular myocardial perfusion occurs during diastole, a lower DBP could potentially lead to myocardial hypoperfusion and associated damage, especially in individuals with left ventricular hypertrophy (which increases oxygen demand) or coronary artery disease (in which oxygen CI indicates confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; DBP, diastolic blood pressure; HR, hazard ratio; and SBP, systolic blood pressure.
*The second and third columns under model 1 display the results of Cox regression analyses relating the primary and secondary outcomes to the randomized SBP intervention (HRs in the second column) and to a cubic spline in the level of baseline DBP with knots at each baseline DBP quintile (HRs in the fourth column compare the hazards of each outcome between a baseline DBPs of 61 and 78 mm Hg), with covariable adjustment for age, sex, and race.
†The fifth and sixth columns display the proportional change in the HR comparing the intensive and standard SBP interventions for each 5-mm Hg increase in DBP under model 2, which includes main effects for the randomized SBP intervention and cubic splines in baseline DBP, plus linear interactions between the randomized SBP intervention and baseline DBP. We present linear interactions between the randomized SBP intervention and baseline DBP because likelihood ratio tests evaluating interactions between the SBP intervention and cubic splines in baseline DBP indicated no evidence of nonlinear interactions (P>0.10 for each outcome). 
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supply is already compromised). In the ARIC (Atherosclerosis Risk In Communities) cohort, lower DBP was associated with higher serum concentrations of cardiac troponin T, a marker of myocardial injury. 24 Almost all SPRINT participants were being treated for hypertension at baseline. Consistent with previous ontreatment reports, our study identified a U-shaped relationship between baseline DBP and the SPRINT primary CVD composite outcome.
Use of an intention-to-treat analysis provides a better way to determine whether the beneficial effects of intensive BP control are modified by level of baseline DBP because it takes advantage of the randomized design. In SPRINT, intensive SBP lowering that also lowered DBP was beneficial rather than hazardous even for those within the lowest quintile of baseline DBP (<68 mm Hg), where the average achieved DBP during follow-up in the intensive arm was <60 mm Hg. Our findings suggest that the association of a higher CVD event rate with lower levels of DBP is more likely to be a result of the clinical characteristics associated with a lower DBP such as age and comorbidities than a response to lowering of DBP per se.
Our findings are consistent with experience in the HOT trial (Hypertension Optimal Treatment), 25 in which 6264 patients were randomly allocated to a target DBP ≤90 mm Hg, 6264 to ≤85 mm Hg, and 6262 to ≤80 mm Hg, and DBP was reduced by 20.3, 22.3, and 24.3 mm Hg, respectively. An intention-to-treat analysis identified no differences in CVD events, CVD mortality, or all-cause mortality between the 3 groups, but a J-shaped relationship was noted between achieved DBP and CVD. In the AASK trial (African American Study of Kidney Disease and Hypertension), participants with CKD were randomly assigned to a MAP target of 102 to 107 or ≤92 mm Hg. 26 Although the intention-totreat analyses by randomized groups did not show an effect of intensive BP lowering, the achieved BP analyses suggested that lower achieved MAP was associated with better kidney outcomes. Thus, analyses based on achieved BP can lead to markedly different inferences than intention-to-treat analyses, in part as a result of confounding and reverse causality.
Tissue perfusion depends on MAP. Because interventions that target lower SBP also reduce DBP, they will decrease the MAP and hence tissue perfusion. In theory, this might be particularly important in those with wider PP (with already lower DBP, and the drop in SBP might have an even greater effect on MAP). However, we also did not find evidence of heterogeneity of the effects of intensive SBP lowering by baseline MAP and PP quintiles.
A strength of the present analysis was our ability to examine the role of baseline DBP on treatment effect with the use of a randomized comparison. Other strengths included the availability of a relatively large sample size and a diverse population with relatively low pretreatment levels of DBP and a high risk for CVD. In addition, SPRINT was a rigorously conducted trial with careful measurement of BP and outcomes data. Weaknesses include the post hoc nature of the analyses and lack of intermediate biomarkers of tissue damage such as cardiac troponin. As with any subgroup analyses of randomized controlled trial data, power might be limited to definitively exclude potential harm of intensive SBP lowering on CVD outcomes in the lowest DBP quintile. Because the 95% confidence interval in the lowest DBP quintile for the primary CVD outcome ranges from 0.57 to 1.07, the potential effects of the intervention range from 43% reduction in primary CVD outcome up to a small 7% increase in risk of primary CVD outcome in this quintile.
Conclusions
Intensive SBP lowering in SPRINT participants led to substantial reductions in DBP and MAP. Although participants with lower DBP at baseline experienced higher rates of major cardiovascular events, SBP lowering appears beneficial across the spectrum of baseline DBP, even among those in the lowest quintile of DBP at baseline. Low levels of DBP, at least within the ranges examined here, should not be an impediment to intensive treatment of hypertension. 
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